Phase 1 safety study of RTL1000 (recombinant T cell receptor ligand) in subjects with multiple sclerosis.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2011
At a glance
- Drugs RTL 1000 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 14 Apr 2010 Results have been presented at AAN 2010.
- 14 Sep 2009 Results presented at EFNS 2009.
- 14 Sep 2009 Secondary endpoint 'Pharmacokinetic parameters' has been met, according to an Artielle ImmunoTherapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History